Less time in a chair and more time on the move, even if it’s a stroll versus a sprint, is the key to keeping cancer at bay.

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events ...

Data demonstrate potential superiority of antibody-based T cell engager CDR404 over TCR-based approaches, consistent with emerging Phase 1 trial signals of ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the ...